Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 2/20 | 0.75 |
| ▸ | NADK | O95544 | 2/20 | 0.74 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.72 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.72 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.72 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.72 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.72 |
| ▸ | SRC | P12931 | 1/20 | 0.72 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.69 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.69 |
| ▸ | IMPDH1 | P20839 | 3/20 | 0.69 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.68 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.68 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.68 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine Diphosphate SCHEMBL570243 | 0.99 | ADH1A (0.74) | ADH1ANADKP2RY1P2RY2P2RX1 | |
| Adenosine Triphosphate SCHEMBL811713 | 0.94 | P2RY1 (0.72) | ADH1ANADKP2RY1P2RY2P2RX1 | |
| Adenosine Phosphate SCHEMBL160972 | 0.93 | P2RY1 (0.75) | ADH1ANADKP2RY1P2RY2P2RX1 | |
| Adenosine Phosphate SCHEMBL27419541 | 0.93 | P2RY1 (0.75) | ADH1ANADKP2RY1P2RY2P2RX1 | |
| Adenosine Diphosphate SCHEMBL11326192 | 0.91 | ADH1A (0.64) | ADH1ANADKP2RY1P2RY2P2RX1 | |
| Niacinamide SCHEMBL28249016 | 0.89 | ADH1A (0.66) | ADH1ANADKP2RY1P2RY2P2RX1 | |
| SCHEMBL811714 | 0.88 | P2RY1 (0.63) | ADH1ANADKP2RY1P2RY2P2RX1 | |
| Adenosine Triphosphate SCHEMBL28796097 | 0.88 | P2RY1 (0.89) | P2RY1P2RY2P2RX1P2RX3P2RX2 | |
| Niacinamide SCHEMBL14861027 | 0.88 | ADH1A (0.84) | ADH1ANADKP2RY1P2RY2P2RX1 | |
| SCHEMBL810819 | 0.88 | P2RY1 (0.69) | ADH1ANADKP2RY1P2RY2P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040156873-A1 | Topically Bioavailable Acne and Rosacea Treatment Compositions | GUPTA SHYAM K (US) | 2004-08-12 | — | — | US | claimed |
| US-20040081672-A1 | Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging | GUPTA SHYAM K (US) | 2004-04-29 | — | — | US | claimed |
| CN-109641814-B | Non-corrosive nitration inhibitor polar solvent preparation | 美国陶氏益农公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-109641814-A | Non-corrosive nitrification inhibitor polar solvent preparation | 美国陶氏益农公司 | 2019-04-16 | — | — | CN | disclosed |
| CN-109496209-A | Non-corrosive nitration inhibitor polar solvent preparation | 美国陶氏益农公司 | 2019-03-19 | — | — | CN | disclosed |
| US-10173943-B2 | Non-corrosive nitrification inhibitor polar solvent formulation | DOW AGROSCIENCES, LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-10173942-B2 | Non-corrosive nitrification inhibitor polar solvent formulation | DOW AGROSCIENCES, LLC (US) | 2019-01-08 | — | — | US | disclosed |
| WO-2017069828-A1 | NON-CORROSIVE NITRIFICATION INHIBITOR POLAR SOLVENT FORMULATION | DOW AGROSCIENCES, LLC (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017069827-A1 | NON-CORROSIVE NITRIFICATION INHIBITOR POLAR SOLVENT FORMULATION | DOW AGROSCIENCES, LLC (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20160332931-A1 | NON-CORROSIVE NITRIFICATION INHIBITOR POLAR SOLVENT FORMULATION | SPECIALTY OPERATIONS FRANCE (FR) | 2016-11-17 | — | — | US | disclosed |
| US-20160332930-A1 | NON-CORROSIVE NITRIFICATION INHIBITOR POLAR SOLVENT FORMULATION | SPECIALTY OPERATIONS FRANCE (FR) | 2016-11-17 | — | — | US | disclosed |
| EP-1896015-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTORS | The Interthyr Corporation (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006124676-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTORS | THE INTERTHYR CORPORATION (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060211752-A1 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | BENAVIDES-PERALTA, URUGUAYSITO LORELEY (UY) | 2006-09-21 | — | — | US | disclosed |
| US-20060147508-A1 | Concurrent Enhancement of Skin Penetration of Organic Base Active Agents and Organic Hydroxy Acid Active Agents as Their Ion-Pair Complexes | BIODERM RESEARCH (US) | 2006-07-06 | — | — | US | disclosed |
| WO-2006023710-A2 | COSMETIC OR PHARMACEUTICAL COMPOSITION FOR SKIN CARE | INFINITY2 HEALTH SCIENCES, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060039887-A1 | Cosmetic or pharmaceutical composition for skin care | INFINITY2 HEALTH SCIENCES, INC. | 2006-02-23 | — | — | US | disclosed |
| US-20040228884-A1 | Ion-pair delivery system for cosmetic and pharmaceutical compositions | GUPTA SHYAM K (US) | 2004-11-18 | — | — | US | disclosed |
| US-20040081672-A1 | Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging | GUPTA SHYAM K (US) | 2004-04-29 | — | — | US | disclosed |
| US-5104787-A | Aqueous nutrient and electrolyte solution: glycosaminoglycans, deturgescent agent, energy source, buffer; diminishes dehydration and inhibits swelling during storage and transfer | CHIRON VISION CORPORATION | 1992-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211752-A1 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | TLR3, IRF3, TLR4 | ADH1A 3345/4885NADK 4677/4885P2RY1 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.